Additionally, a structure harboring the G1202R mutation (PDB code: 9GBE) was identified in complex with the NVL-655 ALK inhibitor for NSCLC, suggesting that lorlatinib may also target this variant (Lin et al., 2024). This evidence concerns the gene ALK and non-small cell lung carcinoma.